3 so 2 nr 3 r 3a nr 3 so 2 u2014 c 1 4 alkyl nr 3 so 2 cf 3 nr 3 so 2 phenyl s o p cf 3 s o p u2014 c 1 4 alkyl s o p phenyl and cf 2 r cf 3 r 5 at each occurrence is selected from cf 3 c 1 6 alkyl phenyl substituted with 0 2 r 6 and benzyl substituted with 0 2 r 6 r 6 at each occurrence is selected from h oh ch 2 r or 2 f cl br i c 1 4 alkyl cn no 2 ch 2 r nr 2 r 2a ch 2 r c o r 2b nr 2 c o r 2b nr 2 c o nr 2 r 2a ch u2550 nh nh 2 nhc u2550 nh nh 2 so 2 nr 2 r 2a nr 2 so 2 nr 2 r 2a and nr 2 so 2 c 1 4 alkyl in a second embodiment the present invention provides novel pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula i or a pharmaceutically acceptable salt form thereof in a third embodiment the present invention provides a novel method for treating or preventing a thromboembolic disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula i or a pharmaceutically acceptable salt form thereof the compounds herein described may have asymmetric centers compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms it is well known in the art how to prepare optically active forms such as by resolution of.